Physician profile
Andre Aguillon
NPI 1760647507
$2,705.41
in general payments reported to CMS, 2019-2025
18 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $166 · 2021: $280 · 2022: $980 · 2023: $296 · 2024: $512 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,176.11 | 2022-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $570.84 | 2019-2025 | |
| Axsome Therapeutics, INC. | $200.15 | 2023-2025 | Sunosi |
| Idorsia Pharmaceuticals US INC | $178.40 | 2023-2024 | Quviviq |
| Harmony Biosciences LLC | $133.51 | 2020-2024 | |
| Pulmonx Corporation | $125.31 | 2021 | |
| Baxter Healthcare | $53.98 | 2022 | |
| Intuitive Surgical, INC. | $47.74 | 2021 | |
| Philips North America LLC | $35.32 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $26.65 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $22.85 | 2024 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $20.89 | 2023 | |
| Novartis Pharmaceuticals Corporation | $20.81 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.69 | 2024 | Ofev |
| Avadel Cns Pharmaceuticals, LLC | $19.81 | 2025 | Lumryz |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $19.53 | 2023 | Giapreza |
| Takeda Pharmaceuticals U.S.A., INC. | $19.29 | 2023 | Glassia |
| Amgen INC. | $13.53 | 2024 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Aguillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.